ViiV releases promising phase 2 data on potential long-acting HIV drugs
by
Contributor since / Followers
Contributor since / Followers
3 weeks ago
Gam1983
- ViiV Healthcare, which is majority owned by GSK (NYSE:GSK), said that two HIV antiretroviral candidates that could be developed into long-acting injectables demonstrated strong efficacy in phase 2 trials.
- Three oral dosage strengths of VH184 (10mg, 50mg, and 300mg) taken every 3 days were